Basis for Immunotherapy for Treatment of Meningiomas
Meningiomas are common tumors that account for approximately one third of CNS tumors diagnosed every year. They are classified by the World Health Organization in grades I-III. Higher grades have an increased rate of growth, invasiveness, rate of recurrence, and worse outcomes than lower grades. Mos...
Main Authors: | Tomas Garzon-Muvdi, Destiny D. Bailey, Mark N. Pernik, Edward Pan |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2020.00945/full |
Similar Items
-
Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management
by: Taylor Anne Wilson, et al.
Published: (2020-11-01) -
Meningioma maligno Malignant meningioma
by: Yvei González Orlandi, et al.
Published: (2011-03-01) -
Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma
by: Daijun Wang, et al.
Published: (2020-11-01) -
Anatomical localization of intracranial grade II meningiomas in North-Eastern Romania
by: A. I. Cucu, et al.
Published: (2019-09-01) -
High Tumor Mitochondrial DNA Content Correlates With an Improved Patient's Outcome in WHO Grade III Meningioma
by: Lingyang Hua, et al.
Published: (2020-09-01)